{
    "data": [
        {
            "id": "1073851",
            "type": "article",
            "attributes": {
                "publishOn": "2012-12-19T16:03:48-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Boston Scientific: Down But Not Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39701",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "109670",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1073851-buy-boston-scientific-down-but-not-out"
            }
        },
        {
            "id": "1037701",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-30T07:18:05-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lpath's Q3 Filing Shines The Way For A Catalyst Filled 2013",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24091",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "108832",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1037701-lpaths-q3-filing-shines-the-way-for-a-catalyst-filled-2013"
            }
        },
        {
            "id": "1031521",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-27T16:20:28-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific Could Benefit From St. Jude Medical's Troubles",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1031521-boston-scientific-could-benefit-from-st-jude-medicals-troubles"
            }
        },
        {
            "id": "997931",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-11T02:38:24-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific - Another Acquisition Despite Questionable Track Record",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/997931-boston-scientific-another-acquisition-despite-questionable-track-record"
            }
        },
        {
            "id": "995681",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-09T14:40:08-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific Gatecrashes Renal Denervation Market With Vessix Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/995681-boston-scientific-gatecrashes-renal-denervation-market-with-vessix-buy"
            }
        },
        {
            "id": "973561",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-02T13:34:32-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Downside Risks To Boston Scientific's $6 Fair Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107859",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/973561-downside-risks-to-boston-scientifics-6-fair-value"
            }
        },
        {
            "id": "947241",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-24T16:30:51-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific's September Earnings Reflect Aggressive Accounting",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "26971",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/947241-boston-scientifics-september-earnings-reflect-aggressive-accounting"
            }
        },
        {
            "id": "939881",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-22T18:19:22-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lpathomab Offers Hope In Billion-Dollar Neurotrauma And Pain Markets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "27571",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107419",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/939881-lpathomab-offers-hope-in-billion-dollar-neurotrauma-and-pain-markets"
            }
        },
        {
            "id": "935121",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-19T09:27:21-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific: Earnings Decline Coupled With A Weak Market Outlook",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "222399",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/935121-boston-scientific-earnings-decline-coupled-with-a-weak-market-outlook"
            }
        },
        {
            "id": "934191",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-18T20:37:58-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific Offers More Muddle-Through",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107329",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/934191-boston-scientific-offers-more-muddle-through"
            }
        },
        {
            "id": "933071",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-18T14:25:34-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earnings Review: Boston Scientific Continues To Suffer End Market Weakness",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "34101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/933071-earnings-review-boston-scientific-continues-to-suffer-end-market-weakness"
            }
        },
        {
            "id": "915681",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-10T09:46:02-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lpath Restarts NEXUS Trial; Breathes New Life Into Shares",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24433",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "106952",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/915681-lpath-restarts-nexus-trial-breathes-new-life-into-shares"
            }
        },
        {
            "id": "912161",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-09T04:54:23-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific - Rhythmia Medical, Another $90 Million Acquisition Highlight Poor Acquisition Track Record",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/912161-boston-scientific-rhythmia-medical-another-90-million-acquisition-highlight-poor-acquisition-track-record"
            }
        },
        {
            "id": "898221",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-01T16:37:35-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "FDA Approves Boston Scientific's Defibrillator, But Stock Fairly Priced",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "106563",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/898221-fda-approves-boston-scientifics-defibrillator-but-stock-fairly-priced"
            }
        },
        {
            "id": "870421",
            "type": "article",
            "attributes": {
                "publishOn": "2012-09-17T07:09:11-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific's Device To Relieve Severe Asthma: A Major Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "105989",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/870421-boston-scientifics-device-to-relieve-severe-asthma-a-major-opportunity"
            }
        },
        {
            "id": "781591",
            "type": "article",
            "attributes": {
                "publishOn": "2012-08-05T02:17:24-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific's President And CEO Agree: It's A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24063",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/781591-boston-scientifics-president-and-ceo-agree-its-a-buy"
            }
        },
        {
            "id": "757411",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-27T15:03:55-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Lpath Shares Could Soar Ahead Of ISONEP Trial",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "27571",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "104239",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/757411-why-lpath-shares-could-soar-ahead-of-isonep-trial"
            }
        },
        {
            "id": "752061",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-26T12:49:25-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Can Boston Scientific Still Be This Bad?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/752061-how-can-boston-scientific-still-be-this-bad"
            }
        },
        {
            "id": "656621",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-13T10:15:20-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "High Option Volume For Boston Scientific",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25036",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/656621-high-option-volume-for-boston-scientific"
            }
        },
        {
            "id": "590511",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-15T11:50:17-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lpath Back In Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24433",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101329",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/590511-lpath-back-in-play"
            }
        },
        {
            "id": "578861",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-10T15:03:02-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Bullish Case For Boston Scientific",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "28431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101124",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/578861-update-bullish-case-for-boston-scientific"
            }
        },
        {
            "id": "543241",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-30T14:37:45-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bullish Case For Boston Scientific Corp",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "28431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100599",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/543241-bullish-case-for-boston-scientific-corp"
            }
        },
        {
            "id": "510521",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-19T11:49:13-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific Has The Tools, But Does It Have The Talent?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/510521-boston-scientific-has-the-tools-but-does-it-have-the-talent"
            }
        },
        {
            "id": "480951",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-05T11:19:20-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lpath: A Solid Pipeline With Good PPS",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "27141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "99550",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/480951-lpath-a-solid-pipeline-with-good-pps"
            }
        },
        {
            "id": "425681",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-11T09:45:05-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Acquisition Could Jump-Start Boston Scientific's Sluggish Cardiac Defibrillator Business",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/425681-acquisition-could-jump-start-boston-scientifics-sluggish-cardiac-defibrillator-business"
            }
        },
        {
            "id": "417171",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-07T09:25:24-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lpath: With Share Offering Done, Now Is The Time To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "27141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98387",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/417171-lpath-with-share-offering-done-now-is-the-time-to-buy"
            }
        },
        {
            "id": "412101",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-05T14:39:40-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Morgan Joseph Expects Triple-Digit Gains For This Pfizer Partner",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24866",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98311",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/412101-why-morgan-joseph-expects-triple-digit-gains-for-this-pfizer-partner"
            }
        },
        {
            "id": "407411",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-02T09:14:07-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific's Guidant Acquisition Led To Fines, Settlements And Penalties; But That's Just The Beginning Of Its Woes",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "26971",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "219726",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/407411-boston-scientifics-guidant-acquisition-led-to-fines-settlements-and-penalties-but-thats-just-the-beginning-of-its-woes"
            }
        },
        {
            "id": "403281",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-29T23:45:59-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lpath Dip May Be Simply A Buying Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23051",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98173",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/403281-lpath-dip-may-be-simply-a-buying-opportunity"
            }
        },
        {
            "id": "400801",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-29T09:35:54-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific Offers Investors Huge Valuation Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98138",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/400801-boston-scientific-offers-investors-huge-valuation-upside"
            }
        },
        {
            "id": "397301",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-28T10:21:36-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific: Overleveraged To The Coronary Stent Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24276",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "219707",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/397301-boston-scientific-overleveraged-to-the-coronary-stent-market"
            }
        },
        {
            "id": "335101",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-02T08:38:38-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific: Struggles Today, Still Hope For Tomorrow?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/335101-boston-scientific-struggles-today-still-hope-for-tomorrow"
            }
        },
        {
            "id": "334542",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-02T04:05:31-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "LPath's Form / Fill Delay Disappoints Investors: Long-Term Buying Opportunity?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24232",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "97329",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/334542-lpaths-form-fill-delay-disappoints-investors-long-term-buying-opportunity"
            }
        },
        {
            "id": "326462",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-30T16:58:17-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Boston Scientific: Earnings Preview",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2290",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/326462-boston-scientific-earnings-preview"
            }
        }
    ]
}